
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics is on track to become a leading player in the biotechnology industry with its innovative TANGO technology and promising drug pipeline targeting haploinsufficiency diseases. With positive data from its first medicine in development and ongoing clinical trials for various genetic diseases, Stoke is positioned for long-term success. Additionally, the company's strong financials and partnerships add further potential for future growth and value creation.
Bears say
Stoke Therapeutics is a biotechnology company with a potentially promising treatment for Dravet syndrome, but their management's decision to wait for full P3 data before offering the drug to patients and payors is concerning. While the OLE data from year four shows positive results for non-seizure symptoms, the main question is what other disease modifications the P3 EMPEROR trial will support. Additionally, the company faces multiple risks, including stock price volatility and intellectual property risks. With a need to raise capital before becoming profitable, there is potential for share dilution for shareholders.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares